Research and Markets (http://www.researchandmarkets.com/research/3gtnvb/parkinsons) has announced the addition of the "Parkinson's Disease Therapeutics Market to 2019 - Pipeline Shows Shift Towards Long Term Disease Management" report to their offering.

Impact of Patent Expiration Unlikely to Be Diminished by New Market Entrants

Due to upcoming patent expirations for four high-profile drugs, the global Parkinson's Disease (PD) market is expected to decline over the forecast period from $3.4 billion in 2012 to $2.9 billion in 2019. However, due to the time delay in drug submission in Canada and Japan, the impact of patent expirations will not be as immediate as in the US and European Union (EU). These patent expirations include Azilect (rasagiline mesylate), Stalevo (levodopa, carbidopa, entacapone) and Comtan (entacapone).

Generic alternatives for these drugs have already been approved, which will result in future generic competition over the forecast period. In addition, the impact of the patent expiration of Mirapex (pramipexole dihydrochloride) and Exelon (rivastigmine tartrate) in 2010 and 2012 will continue to halt the market growth over the forecast period.

Although the approval of a few market entrants is anticipated over the forecast period, this is not expected to be significant enough to diminish the impact of generic erosion. As new entrants will be competing against cheaper generic products, they are not expected to demand a premium price. An example is Rytary (carbidopa, levodopa) which was developed by Impax Laboratories. The extended-release formulation of levodopa/carbidopa will face intense competition against generic alternatives to Sinemet if approved.

One of the limitations of existing dopaminergic therapies is the motor complications that arise after several years of treatment. Levodopa-associated motor complications such as the wearing-off phenomenon and dyskinesia can profoundly affect the quality of life in patients with PD. Around 50% of patients develop motor complications after five years of levodopa treatment (Lang and Lozano, 1998). However, current treatment options for these complications remain very limited.

As reflected in the pipeline, treatments focusing on improving levodopa-associated complications have received a considerable amount of attention in recent years. Key pipeline candidates have been under investigation for treating wearing-off and Levodopa-Induced Dyskinesia (LID). They include tozadenant, mavoglurant and dipraglurant, which are developed by Biotie Therapies, Novartis and Addex Therapeutics, respectively. In particular, mavoglurant and dipraglurant have demonstrated promising antidyskinesia effects in Phase II. These new developments may potentially bring changes in the future treatment algorithm as side effects of dopaminergic therapies become more manageable.

High Number of Neuroprotective Targets in Early Pipeline

With existing products focusing on symptomatic relief, a disease-modifying treatment remains an urgent unmet need in PD. The current PD pipeline is made up of 21% neuroprotective targets. The majority, 87%, are currently in discovery and Preclinical development, while the remaining molecules are distributed in Phase I and II. These targets represent innovation in the pipeline and could become an effective disease-modifying treatment in the future.

However, that development of such treatment remains challenging, with several obstacles yet to be overcome. The absence of neuroprotective candidates in the late pipeline has been a recurring issue. Of all the challenges, the most urgent is the need for a reliable biomarker for PD that can accelerate the development of treatment.

Key Topics Covered:

List of Tables

List of Figures

Introduction

Marketed Products

Pipeline for Parkinson's Disease

Market Forecast to 2019

Deals and Strategic Consolidations

Appendix

For more information visit http://www.researchandmarkets.com/research/3gtnvb/parkinsons

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System